CHUK and colorectal cancer: Colomer et al.7 demonstrated that IKKα inhibition synergistically enhance the therapeutic potential of the standard of care therapy in colorectal cancer (5-FU plus irinotecan), leading to the eradication of chemotherapy-resistant metastatic human tumors in vivo.